Skip to main content
. Author manuscript; available in PMC: 2019 Apr 25.
Published in final edited form as: Semin Hematol. 2018 Apr 25;55(2):87–93. doi: 10.1053/j.seminhematol.2018.04.011

Table 4.

Risks and benefits of high to low intensity conditioning regimen with MRD

Myeloablative
(e.g. Bu-Cy-ATG)		 Reduced Intensity/Toxicity Low Intensity
(e.g. 300 rads TBIalemtuzumab)

  • Full doses of 2 or more chemo combination

  • Mild to moderate disease

  • Children and young adults

  • Gonadal toxicity; infertility in all

  • 10-15% GVHD, 5-10% mortality

  • Mixed chimerism uncommon

  • Shortest course (<6 months) immunosuppression

  • Reduced doses of 2 or more chemo combination

  • Mild to moderate disease

  • Children and young adults

  • Less gonadal toxicity; infertility in most

  • 10-15%GVHD, 5-10% mortality

  • Mixed chimerism uncommon

  • Shorter course (about 6-12months) immunosuppression

  • Low dose chemo, antibody, and/or TBI combination

  • Any disease

  • Any age

  • Most potential for fertility preservation

  • 0% GVHD, 5-10% mortality

  • Mixed chimerism in majority

  • Longer course (about 12 months) immunosuppression
HHS Vulnerability Disclosure